Rapid fluorometric determination of ticagrelor in tablets and rat plasma: Application to pharmacokinetics study.

[1]  J. Spence,et al.  Antiplatelet Therapy in Ischemic Stroke and Transient Ischemic Attack. , 2019, Stroke.

[2]  D. Danielak,et al.  Development of an LC-MS/MS method for simultaneous determination of ticagrelor and its active metabolite during concomitant treatment with atorvastatin. , 2019, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[3]  E. Oqueli,et al.  Ticagrelor-associated ventricular pauses: a case report and literature review , 2018, European heart journal. Case reports.

[4]  Nathalie R Wingert,et al.  Application of Quality by Design to optimize a stability‐indicating LC method for the determination of ticagrelor and its impurities , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[5]  R. Sarvesh,et al.  ANALYTICAL METHOD DEVELOPMENT AND VALIDATION STUDIES OF TICAGRELOR TABLETS BY RP-HPLC , 2017 .

[6]  T. P. Aneesh,et al.  BIOANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF TICAGRELOR BY RP-HPLC , 2017 .

[7]  Mupeng Li,et al.  An HPLC-MS/MS Method for the Quantitative Determination of Ticagrelor and its Active Metabolite AR-C124910XX in Human Plasma and its Application to a Clinical Study , 2017 .

[8]  M. Steppe,et al.  HPLC method for simultaneous analysis of ticagrelor and its organic impurities and identification of two major photodegradation products , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[9]  Y. Abdallah,et al.  Highly Sensitive Carbon Based Sensing Utilizing Titanium Dioxide Nanoparticles and Multiwalled Carbon Nanotubes for Determination of Ticagrelor: Pharmacokinetics Application , 2017 .

[10]  S. Zhong,et al.  Simultaneous Determination of Ticagrelor and Its Metabolites in Human Plasma and Urine Using Liquid Chromatography-Tandem Mass Spectrometry. , 2016, Journal of analytical toxicology.

[11]  N. Kapuriya,et al.  AN IMPROVED ASSAY METHOD FOR THE ESTIMATION OF TICAGRELOR HYDROCHLORIDE BY REVERSE PHASE LIQUID CHROMATOGRAPHY , 2016 .

[12]  H. Elmansi,et al.  Simultaneous determination of metoclopramide and aspirin by spectrofluorimetric technique: application to pharmaceutical formulations and human plasma , 2016 .

[13]  T. P. Aneesh,et al.  Development and validation of RP- HPLC method for determination of ticagrelor in pharmaceutical dosage formulation , 2016 .

[14]  Marc P. Bonaca,et al.  Long-term use of ticagrelor in patients with prior myocardial infarction. , 2015, The New England journal of medicine.

[15]  A. Mendez,et al.  Determination of the New Antiplatelet Agent Ticagrelor in Tablets by Stability-Indicating HPLC Method , 2014 .

[16]  Juan Maya,et al.  Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers , 2012, Platelets.

[17]  D. Goel.  Ticagrelor: The first approved reversible oral antiplatelet agent , 2013, International journal of applied & basic medical research.

[18]  M. de la Guardia,et al.  Handbook of green analytical chemistry , 2012 .

[19]  Henrik Sillén,et al.  Determination of unbound ticagrelor and its active metabolite (AR-C124910XX) in human plasma by equilibrium dialysis and LC-MS/MS. , 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[20]  Henrik Sillén,et al.  Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[21]  R. Teng,et al.  Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. , 2010, British journal of clinical pharmacology.

[22]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[23]  C. Cannon,et al.  Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. , 2007, Journal of the American College of Cardiology.

[24]  Soraya Dhillon,et al.  Basic pharmacokinetics , 2006 .

[25]  J. Miller,et al.  Statistics and chemometrics for analytical chemistry , 2005 .

[26]  L. Capitán-Vallvey,et al.  SPECTROFLUORIMETRIC DETERMINATION OF ACETYLSALICYLIC ACID AND CODEINE MIXTURES IN PHARMACEUTICALS , 2001 .